A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.

Robert W Lentz Tyler J Friedrich Patrick J Blatchford Kimberley R Jordan Todd M Pitts Hannah R Robinson S Lindsey Davis Sunnie S Kim Alexis D Leal Matthew R Lee Meredith R N Waring Anne C Martin Adrian T A Dominguez Stacey M Bagby Sarah J Hartman S Gail Eckhardt Wells A Messersmith Christopher H Lieu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Pembrolizumab, binimetinib, and bevacizumab failed to meet its primary endpoint of higher ORR compared to historical control data, demonstrated a high disease control rate, and demonstrated acceptable tolerability in refractory MSS mCRC.

Keyphrases

phase ii study
open label
advanced non small cell lung cancer
metastatic colorectal cancer
locally advanced
placebo controlled
electronic health record
randomized controlled trial
clinical trial
big data
squamous cell carcinoma
machine learning
double blind
epidermal growth factor receptor
rectal cancer